DM
ALBO

Deerfield Management’s Albireo Pharma Inc ALBO Stock Holding History

Deerfield Management’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-120,000
Closed -$3.96M – 109
2018
Q3 		$3.96M Hold
120,000
– – 0.14% 90
2018
Q2 		$4.26M Hold
120,000
– – 0.15% 99
2018
Q1 		$3.91M Buy
+120,000
New +$4.04M 0.14% 99

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Deerfield Management's ALBO Position: Q4 2018 in Review

Deerfield Management sold out of Albireo Pharma Inc (ALBO) in Q4 2018, closing a stake of 120,000 shares — an estimated $3.96M sold.

Deerfield Management first reported a position in ALBO in Q1 2018 and held it in 3 quarters. The position peaked at $4.26M in Q2 2018. 68 funds tracked by Wall St. Rank hold ALBO as of Q4 2018.

  • Deerfield Management reported no remaining Albireo Pharma Inc position as of Q4 2018 after selling out during the quarter.
  • Deerfield Management sold 120,000 Albireo Pharma Inc shares in Q4 2018, an estimated $3.96M.
  • Deerfield Management first reported a position in Albireo Pharma Inc in Q1 2018 and held it in 3 quarters.
  • Deerfield Management's Albireo Pharma Inc position peaked at $4.26M in Q2 2018.
  • 68 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q4 2018.

Based on Deerfield Management's 13F filing for Q4 2018, filed 14 Feb 2019.